Medtronic Scores Expanded FDA Nod For Cardiac Cryoablation Catheters In Pediatric Patients With Heart Rhythm Condition

The FDA has approved Medtronic plc's MDT Freezor and Freezor Xtra Cardiac Cryoablation Catheters to treat pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT).

• The Freezor and Freezor Xtra Catheters are flexible, single-use devices to freeze cardiac tissue and block unnecessary electrical signals within the heart. 
• Cryoablation can reduce the risk of permanent AV block, a complication of AVNRT procedures performed with radiofrequency (RF) ablations resulting in the partial or complete interruption of the heart's electrical signals, which disrupts the heart rhythm.
• Related: Medtronic Issues Voluntary Recall For TurboHawk Plus Directional Atherectomy System.
• The Freezor cardiac cryoablation catheter was first commercially available in the U.S. for adult use of AVNRT in 2003, followed by the Freezor Xtra cardiac cryoablation catheter in 2016. 
• Price Action: MDT shares are down 0.77% at $100.92 during the market session on the last check Friday.